132
Views
6
CrossRef citations to date
0
Altmetric
Hematological Malignancy: Current Clinical Practice

Evaluation of factors associated with recruitment in hematological clinical trials: a retrospective cohort study

, , &
Pages 373-377 | Published online: 18 Jul 2013

References

  • Tournoux C, Katsahian S, Chevret S, Levy V. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 2006; 106: 258–270.
  • Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720–2726.
  • Lemieux J, Goodwin PJ, Pritchard KI et al. Identification of cancer care and protocol characteristics associated with recruit-ment in breast cancer clinical trials. J Clin Oncol 2008; 26: 4458–4465.
  • Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363: 263–270.
  • Hebert-Croteau N, Brisson J, Lemaire J, Latreille J. The benefit ofparticipating to clinical research. Breast Cancer Res Treat 2005; 91: 279–281.
  • Canadian Cancer Society’s Steering Committee. Canadian cancer statistics 2009. Toronto, Ont.: Canadian Cancer Society, 2009.
  • Meropol NJ, Buzaglo JS, Millard J et al. Barriers to clinical trialparticipation as perceived by oncologists and patients. J Natl Compr Cane Netw 2007; 5: 655–664.
  • Hunter CP, Frelick RW, Feldman AR et al. Selection factors in clinical trials: results from the community clinical oncology program physician's patient log. Cancer Treat Rep 1987; 71: 559–565.
  • Hjorth M, Holmberg E, Rodjer S, Taube A, Westin J. Physicians'attitudes toward clinical trials and their relationship to patient accrual in a Nordic multicenter study on myeloma. Control Clin Trials 1996; 17: 372–386.
  • Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21: 3933–3939.
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
  • Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002; 137: 10–16.
  • Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol 1998; 51: 69–79.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.